PC/BPA Group of PlasticsEurope statement in response to ECHA’s Member State Committee (MSC) vote on the French proposal to identify Bisphenol A (BPA) as Substance of Very High Concern (SVHC) because of alleged endocrine disrupting (ED) properties for human health.
Industry highly concerned about Member State decision which is not consistent with the weight of the scientific evidence “We do not understand the decision of the Member State Committee to support the Annex XV
dossier on BPA put forward by the French authorities. The decision is in contrast with our thorough assessment of the scientific data on BPA. Furthermore, it is opposite to the conclusion reached by the European Food Safety Authority (EFSA): The independent EFSA expert panel concluded that based on the WHO criteria BPA is not an endocrine disruptor,” says Jasmin Bird of the PC/BPA Group. “We are highly concerned about this development. We believe that this weakens the strong principle of science-based regulatory decisions in the EU, and will result in further uncertainty without providing benefit to the safety of consumers.”
EFSA concludes BPA is not an endocrine disruptor For BPA, a comprehensive scientific evaluation, which follows weight-of-evidence principles, was carried out by the European Food Safety Authority (EFSA) and published in 2015. It investigated the substance´s intrinsic properties together with the actual exposure of humans in order to determine appropriate measures to ensure safe use. In their assessment, EFSA’s independent researchers reviewed all available scientific studies on BPA, including the literature on potential endocrine-related effects of BPA. In its evaluation, EFSA concluded, that there is no consumer health risk from current BPA exposure. On endocrine disruption, EFSA’s expert panel concluded that “based on the WHO criteria, it is not possible to conclude that BPA is an endocrine disruptor”*.